Skip to main content

Vizamyl FDA Approval History

Last updated by Judith Stewart, BPharm on June 22, 2020.

FDA Approved: Yes (First approved October 25, 2013)
Brand name: Vizamyl
Generic name: flutemetamol F 18
Dosage form: Injection
Company: GE Healthcare
Treatment for: Diagnosis and Investigation

Vizamyl (flutemetamol F 18) is a PET amyloid imaging agent for the evaluation of Alzheimer's disease or other cognitive disorders.

Development timeline for Vizamyl

DateArticle
Oct 25, 2013Approval FDA Approves Vizamyl Brain Imaging Drug to Help Evaluate Patients for Alzheimer’s Disease, Dementia
Jan  8, 2013GE Healthcare Announces Acceptance of Applications for Review of Investigational Imaging Agent [18F]Flutemetamol in the United States and Europe

See also

Vizamyl (flutemetamol F 18) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer